Browse > Article
http://dx.doi.org/10.5478/MSL.2016.7.3.55

LC-MS/MS Method for Simultaneous Analysis of Growth Hormone-Releasing Peptides and Secretagogues in Human Urine  

Min, Hophil (Doping Control Center, Korea Institute of Science and Technology)
Han, Boyoung (Doping Control Center, Korea Institute of Science and Technology)
Sung, Changmin (Doping Control Center, Korea Institute of Science and Technology)
Park, Ju-Hyung (Doping Control Center, Korea Institute of Science and Technology)
Lee, Kang Mi (Doping Control Center, Korea Institute of Science and Technology)
Kim, Ho Jun (Doping Control Center, Korea Institute of Science and Technology)
Kim, Ki Hun (Doping Control Center, Korea Institute of Science and Technology)
Son, Junghyun (Doping Control Center, Korea Institute of Science and Technology)
Kwon, Oh-Seung (Doping Control Center, Korea Institute of Science and Technology)
Lee, Jaeick (Doping Control Center, Korea Institute of Science and Technology)
Publication Information
Mass Spectrometry Letters / v.7, no.3, 2016 , pp. 55-63 More about this Journal
Abstract
Growth hormone (GH)-releasing peptides (GHRPs) and GH secretagogues (GHSs) are listed in the World Anti-Doping Agency (WADA) Prohibited List. In the present study, we developed and validated a method for the simultaneous analysis of seven GHRPs (alexamorelin, GHRP-1, -2, -4, -5, -6, and hexarelin) and three GHSs (anamorelin, ibutamoren, and ipamorelin) in human urine. Method validation was performed at minimum required performance levels specified by WADA technical documents (2 ng/mL) for all substances, and the method was validated with regard to selectivity (no interference), linearity (R2 > 0.9986), matrix effects (50.0%-141.2%), recovery (10.4%-100.8%), and intra- (2.8%-16.5%) and inter-day (7.0%-22.6%) precisions. The limits of detection for screening and confirmation were 0.05-0.5 ng/mL and 0.05-1 ng/mL, respectively.
Keywords
Doping control analysis; Growth hormone; GHRP; GHS; Method validation;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Saugy, M.; Robinson, N.; Saudan, C.; Baume, N.; Avois, L.; Mangin, P. Brit J. Sport Med. 2006, 40, Suppl 1, i35.   DOI
2 Saugy, M.; Cardis, C.; Schweizer, C.; Veuthey, J. L.; Rivier, L. J. Chromatogr. B. 1996, 687, 201.   DOI
3 Okano, M.; Nishitani, Y.; Sato, M.; Ikekita, A.; Kageyama, S. Drug Test Anal. 2010, 2, 548.   DOI
4 Baumann, G. P. Endocr. Rev. 2012, 33, 155.   DOI
5 Bowers, C. Y.; Sartor, A. O.; Reynolds, G. A.; Badger, T. M. Endocrinology 1991, 128, 2027.   DOI
6 Arvat, E.; Maccario, M.; Di Vito, L.; Broglio, F.; Benso, A.; Gottero, C.; Papotti, M.; Muccioli, G.; Dieguez, C.; Casanueva, F. F.; Deghenghi, R.; Camanni, F.; Ghigo, E. J. Clin. Endocr. Metab. 2001, 86, 1169.
7 Garcia, J. M.; Polvino, W. J. Growth Horm. Igf. Res. 2009, 19, 267.   DOI
8 Svensson, J.; Boguszewski, C. L.; Shibata, F.; Carlsson, B.; Carlsson, L. M.; Bengtsson, B. A. Growth Horm Igf. Res. 2003, 13, 1.   DOI
9 Thomas, A.; Hoppner, S.; Geyer, H.; Schanzer, W.; Petrou, M.; Kwiatkowska, D.; Pokrywka, A.; Thevis, M. Anal. Bioanal. Chem. 2011, 401, 507.   DOI
10 Okano, M.; Sato, M.; Ikekita, A.; Kageyama, S. Rapid Commun. Mass Spectrom. 2010, 24, 2046.   DOI
11 Thomas, A.; Delahaut, P.; Krug, O.; Schanzer, W.; Thevis, M. Anal. Chem. 2012, 84, 10252.   DOI
12 Sobolevsky, T.; Krotov, G.; Dikunets, M.; Nikitina, M.; Mochalova, E.; Rodchenkov, G. Drug Test Anal. 2014, 6, 1087.   DOI
13 Mazzarino, M.; Calvaresi, V.; de la Torre, X.; Parrotta, G.; Sebastianelli, C.; Botre, F. Forensic Toxicol. 2015, 33, 321.   DOI
14 World Anti-Doping Agency. 2015, Technical Document for minimum required performance levels. https://www.wada-ama.org/en/resources/science-medicine/td2015-mrpl. Accessed 22 May 2015.